Zecotek Receives Favourable Markman Ruling
Singapore, May 14, 2014 – Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the United States District Court of Ohio issued its patent claim construction ruling, or Markman Order, yesterday regarding the ongoing patent infringement action against defendants Saint-Gobain Corporation and Philips. The joint claims construction hearing, also known as the Markman hearing, was held before the Court on July 1 and 2, 2013.
In a Markman Order, the presiding district court sets out the meaning of certain disputed patent claim language present in the patent. The interpretation of the language in the patent is then applied during the action in the determination of infringement and validity of the patent claim. The Markman Order can play a significant role in the progress and outcome of patent infringement litigation.
In the Order issued yesterday, the Court adopted interpretations that Zecotek believes are favorable on the key terms in the litigation dispute.
The lawsuit, filed on February 23, 2012, alleges that Saint-Gobain’s LYSO crystals infringe Zecotek’s patent, and that Philips infringes by using those crystals in the PET scanners it sells.
“We are very pleased with the Court’s interpretations of key terms presented at the Markman Hearing,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “We remain confident in our position and look forward to a just resolution of this action.”
U.S. Patent No. 7,132,060, granted to Zecotek on November 6, 2006, is part of Zecotek’sportfolio of over 50 patented and patent pending novel photonic technologies. The patent covers the substances and chemical formulations used to grow lutetium fine silicate (LFS) scintillation crystals which are characterized by their combined high light yield and ultra-fast decay times and are typically used in medical scanning devices.
– 30 –
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Laser Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances and joint ventures with leading industry partners including Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit Zecotek Photonics, follow @zecotek on Twitter and “like” us in Facebook.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For Additional Information Please Contact:
Zecotek Photonics Inc.
T: (604) 783-8291
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.